"Pills and pulses": hybrid therapy for atrial fibrillation.
Nonpharmacologic techniques are being increasingly applied to the treatment of atrial fibrillation (AF). None of these techniques (other than maze surgery) begins to approach 100% efficacy for long-term elimination of arrhythmia. This review examines the evidence for "hybrid" therapy, using combinations of drug and nonpharmacologic treatments. The immediate success rate of electrical cardioversion can be increased with amiodarone or ibutilide, and a number of drugs reduce the risk of AF recurrence. Preventing or reversing electrical atrial remodeling is an attractive strategy for maintenance of sinus rhythm. However, the available evidence (relating to the use of verapamil) is limited and conflicting. Ablation of the cavotricuspid isthmus is effective when antiarrhythmic drugs given for AF give rise to typical flutter. Isthmus and other right atrial linear lesions are poor as a sole therapy for AF, but better when drugs are added. Better still is the combination of left atrial linear lesions with drugs. In patients with AF recurrence following focal ablation/pulmonary vein isolation procedures, drugs are an alternative to extensive linear ablation. Some studies indicate that pacing to prevent AF may be effective, but rarely without continued antiarrhythmic drug therapy. This may represent a specific effect or simply improved drug tolerance. Drugs also might assist pacemaker therapy by increasing the proportion of atrial arrhythmias that are highly organized and thus amenable to antitachycardia pacing. This and other forms of hybrid therapy will remain the subject of conjecture in the absence of controlled clinical trials, which are urgently needed.
Murgatroyd
Francis D
FD
Cardiac Electrophysiology Unit, Papworth Hospital, Cambridge, United Kingdom. francis@sinusrhythm.com
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000628:therapy*; D002304:Cardiac Pacing, Artificial; D017115:Catheter Ablation; D003131:Combined Modality Therapy; D004554:Electric Countershock; D006801:Humans
D000889:Anti-Arrhythmia Agents